AUTHORS
Sireesha Vutukuri, MD, Nicholas Short, MD2, Yesid Alvarado Valero, MD3, Courtney DiNardo, MD, MSCE4, Maro Ohanian, DO5, Naveen Pemmaraju, MD6, Kelly Sharon Chien, MD7, Alex Bataller, MD, PhD8, Alexandre Bazinet, MD, MSc9, Ian Bouligny, M.D.10, Danielle Hammond, MD11, Joby Joseph12, Heather Schneider, BSN, RN13, Guillermo Garcia-Manero, MD14, Guillermo Montalban-Bravo, MD15
AFFILIATIONS
1 UT MD Anderson Cancer Center, Houston, Texas, United States
2 UT MD Anderson Cancer Center, Houston, Texas, United States
3 UT MD Anderson Cancer Center, Houston, Texas, United States
4 UT MD Anderson Cancer Center, Houston, Texas, United States
5 UT MD Anderson Cancer Center, Houston, Texas, United States
6 UT MD Anderson Cancer Center, Houston, Texas, United States
7 UT MD Anderson Cancer Center, Houston, Texas, United States
8 UT MD Anderson Cancer Center, Houston, Texas, United States
9 UT MD Anderson Cancer Center, Houston, Texas, United States
10 UT MD Anderson Cancer Center, Houston, Texas, United States
11 UT MD Anderson Cancer Center, Houston, Texas, United States
12 UT MD Anderson Cancer Center, Houston, Texas, United States
13 UT MD Anderson Cancer Center, Houston, Texas, United States
14 UT MD Anderson Cancer Center, Houston, Texas, United States
15 UT MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background:
Patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) who fail hypomethylating agents (HMAs) have poor outcomes and limited treatment options. Lysine-specific demethylase 1 (LSD1) regulates myeloid differentiation through the GFI1b/CoREST transcriptional complex, providing a rationale for combining LSD1 inhibition with azacitidine (AZA). Preliminary results from this ongoing study were previously reported (EHA 2024). We report updated safety and efficacy from an expanded cohort.
Methods:
This single center phase I/II trial (NCT04734990) enrolled patients with intermediate-1 or higher-risk MDS or CMML who progressed after or failed ≥6 cycles of prior HMA therapy. A total of 6 dose levels of seclidemstat (150-900mg orally twice daily, days 1-28) combined with AZA 75 mg/m² (days 1–7, every 28 days) were planned to be evaluated. Primary endpoints included safety, dose-limiting toxicities (DLTs), and identifying recommended phase II dose (RP2D). Secondary endpoints included overall response rate (ORR), duration of response, and survival. Responses were assessed using IWG 2006 criteria; a subset was evaluated by IWG 2023 criteria.
Results:
As of July 2026, 24 patients were enrolled across five dose levels (150–750 mg BID). Median age was 74 years (range, 45–84); 71% were male. Diagnoses included MDS 73%(n=20) and CMML 17% (n=4). Patients were heavily pretreated (median 2 prior therapies, range 1–5); all received prior HMAs, 38% (n=9) prior venetoclax, and 17% (n=4) prior allogeneic stem cell transplantation (allo-SCT). A total of 14 (58%) and 5 (21%) had high or very high risk by IPSS-M, respectively. Common baseline mutations included TP53 (38%), ASXL1 (33%), SRSF2 (29%), TET2 (29%), RUNX1 (17%), DNMT3A (17%), and EZH2 (13%).
Two DLTs were observed through five dose levels including grade 3 acute kidney insufficiency and grade 4 encephalopathy. Grade ≥3 treatment-emergent adverse events occurred in 71% of patients and consisted primarily of infections (17%), acute kidney injury (13%), sepsis (8%), febrile neutropenia (8%), and electrolyte abnormalities (8%). Acute kidney injury was reversible and mostly observed during cycle 1 of therapy during combination with azacitidine. Three Grade 5 events were observed including acute respiratory failure, ARDS and intracranial hemorrhage, none of which were related to study drug. Overall, toxicities were consistent with advanced MDS/CMML and prolonged cytopenia. A total of 3 (13%) of patients required dose reductions of seclidemstat and 6 (25%) of azacitidine. Multiple dose reductions were required in 1 (4%) patient. Dose interruptions of seclidemstat due to treatment-emergent toxicities were required in 1 (4%) patient. Patients discontinued treatment due to lack of response (n=9, 38%), AML transformation (n=3, 13%; including one patient with AML and death), death without AML transformation (n=3, 13%), patient decision (n=2, 8%), treatment-related toxicity (n=2, 8%), transplant (n=1, 4%), relapse (n=1, 4%), clinical hold (n=1, 4%), poor compliance (n=1, 4%), and disease progression (n=1, 4%).
The median number of administered cycles of therapy was 3 (range 1-14). Among 23 response-evaluable patients, ORR was 30% (7/23), including 1 complete response (CR), 5 marrow complete responses (3 with hematologic improvement and/or cytogenetic response), and 1 hematologic improvement. The median number of cycles to best response was 2 (range,1-7). Progressive disease was observed in 2 patients (9%). Among patients with MDS, by 2023 IWG criteria, responses included CR (n=1), CRbi (n=1), and CRuni (n=1). Median time to best response was 2 cycles (range, 1–7). Responses were observed across multiple dose levels, including patients with TP53-mutated disease and prior venetoclax exposure. One patient with TP53-mutated therapy-related MDS achieved CR and proceeded to allo-SCT. With a median follow-up of 28 months, the median overall survival was 10 months (95% confidence interval [CI], 6–19), while the median leukemia-free survival was 4 months (95% CI, 3–5) with a median follow-up of 4 months.
Conclusions:
Seclidemstat combined with azacitidine demonstrated modest clinical activity in heavily pretreated patients with higher-risk MDS and CMML after HMA failure, including patients with TP53-mutant disease or prior venetoclax.
DISCLOSURES
Sireesha Vutukuri, MD: No relevant conflicts of interest to declare.